



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Chatterjee *et al.*

Appl. No.: 10/091,538

Filed: March 7, 2002

For: **Improved In Vitro Synthesis System**

Confirmation No.: 8240

Art Unit: 1652

Examiner: Prouty, Rebecca E..

Atty. Docket: 0942.5250001/RWE/AWL

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO REQUEST TO ELECT A SPECIES

Sir:

In response to the Office Action mailed June 2, 2006, applicant petitions currently herewith for a one (1) month extension of time, extending time to respond to and including August 2, 2006, and submits the following remarks.

In response to the requirement to elect species, Applicants elect the species set forth in Group VI, rec BCD (Exonuclease V). This election is made with traverse. Claims readable on this species are: 1, 16, 17, 28, 30, 39, 41, 51-57, 60-62, 69, 70, 77, 78, and 85-96, with claims 1, 16, 17, 28, 30, 39, 41, 51-57, 60-62, 69, 70, 77, 78, and 85-96 being generic claims.

Prompt and favorable reply to this response is respectfully requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Elizabeth A. Orr", with a stylized flourish at the end.

Elizabeth A. Orr, Ph.D.
Patent Agent
Invitrogen Corp.
Registration No. 45,937

Date: August 2, 2006

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600